ReviewApplied microbiology and biotechnology2021
Tissue culture-based genetic improvement of fava bean (Vicia faba L.): analysis on previous achievements and future perspectives.
Review in Applied microbiology and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 9 citations in OpenAlex.
- Advancements and prospectives of sugar beet (Beta vulgaris L.) biotechnology.Applied microbiology and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fava bean is an extremely important legume and serves immense potential to function as an ingredient as pulse proteins in human diet. Bearing the proficiency of yielding magnanimous amount of functional and nutritional ingredients, this bean deserves to replace any other leguminous crop too. The instability of fava bean in its yield makes breeding for crop improvement difficult, and its high susceptibility to a number of abiotic and biotic stresses additionally results in unstable yields. The self-incompatibility leads to the formation of a limited genetic pool and shows a slow progress in breeding. The plant is highly recalcitrant, making it an onerous task to micropropagate or regenerate fava beans under in vitro conditions. Another fly in the ointment is the release of phenolic compounds by the plant. There are several endeavours that have been made to establish in vitro regeneration, protoplast culture, and genetic transformation and to genetically improve this plant. Nonetheless there are a number of promising cutting-edge technologies that are yet to be harnessed in order to ensure its comprehensive and sustainable genetic improvement. The in vitro-based technologies of this legume and its untraveled path in the plant tissue culture-mediated approaches can assist further genetic manipulation of this plant species in a smoother manner and at an exponential rate. Creation of a single review comprising all the updates and genetic advancements in fava bean is an absolute necessity of the hour. Thus, the importance of this review remains at the peak as it covers a vast range of information, starting from the basic description to the utmost modern stages of advancement in the selected crop. Overall interpretation of the review is aimed at encouraging readers to focus on almost all possible dimensions of international research, already executed, and is being executed in fava bean, thereby helping to understand the demand and advantages of the crop, even at the molecular level.Key points• Fava bean, commonly known as "poor man's meat", is a protein-rich legume with multiple nutritional and pharmacological benefits.• Its highly recalcitrant response makes in vitro interventions quite challenging for its genetic improvement.• This review delves into biotechnological interventions for its advancements to date and highlights major hurdles and potential research solutions to ensure comprehensive genetic improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.